Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-23T16:49:33.032Z Has data issue: false hasContentIssue false
  • English
  • Français

384 – The Use of Agomelatina in Drug Addicted Patients with Psychiatrics Disorders

Published online by Cambridge University Press:  15 April 2020

M.C. Pieri  and
A.C. Comaschi
M.C. Pieri
Affiliation:
Mental and Drug Addiction, Drug Addiction Unit Bologna East, Bologna, Italy
A.C. Comaschi
Affiliation:
Mental and Drug Addiction, Drug Addiction Unit Bologna East, Bologna, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Agomelatine is an innovative antidepressant with new mode of action: it's an agonist of melatoninergic receptors MT1 and MT2 and 5HT2c antagonist.

The idea of this study was to assess the use of agomelatine in patients treated in our center for drug addiction in Bologna (SERT), and in particular:

  • patients with heroin abuse treated with full/partial opioid agonists (methadone, buprenorphine, Buprenorphine/naloxone)

  • patients treated for alcohol abuse

  • patients who failed to antidepressants and treated with oppioid agonist

  • patients treated for benzodiazepines abuse

Objective:

Of the study is To evaluate the improvement of mood, anxiety and sleep disorders in patients treated with agomelatine and affected by drug addiction (heroin, alcohol and benzodiazepine

The efficacy of agomelatine was assessed by investigator at T0 and at monthly visit up to 6 months using HAM-A, HAM-D21, VAS for craving VAS for the quality of sleep.

  • Weight, number of hours slept and quality of life were evaluated

  • Blood parameters were assessed at T0 and T6

  • Heroin, cocaine and cannabinoid metabolites were evaluated.

Conclusion:

We evaluated the efficacy of agomelatine on top of conventional treatments for drug addiction in 3 different groups (heroine, alcohol and sedatives addiction). In all three groups we’ve observed the improvement over time in depressive symptoms and anxiety symptoms. We’ve noticed an important reduction of craving. The quality of sleep and the time of sleeping have markedly improved. The quality of life was increased in all patients treated with agomelatine.

Type
Abstract
Information
European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E37
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.